ALKS : Summary for Alkermes plc - Ordinary Shares - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Alkermes plc (ALKS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.46 +0.81 (+1.48%)
At close: 4:00PM EST
People also watch
ALXN INCY BMRN NBIX VRTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 54.65
Open 54.76
Bid 22.33 x 100
Ask 59.87 x 2000
Day's Range 54.76 - 56.39
52 Week Range 27.14 - 63.69
Volume 614,714
Avg. Volume 1,224,095
Market Cap 8.43B
Beta 2.01
PE Ratio (TTM) -32.62
EPS (TTM) -1.7
Earnings Date Feb 23, 2017 - Feb 27, 2017
Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 64.25
Trade prices are not sourced from all markets
  • Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More
    Insider Monkey 3 days ago

    Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More

    Michael Kramer’s Mott Capital just released its Q4 letter to investors, which discussed the fund’s trying 2016 and some of its portfolio moves during the fourth quarter of last year. The fund, which uses a “thematic growth strategy” that couples financial analysis with the latest trends to uncover potential investments, dipped by 2.10% net of […]

  • Barrons.com 11 days ago

    Top Biotech Picks: "The Strong Will Survive And Thrive"

    After two volatile years, the biotech sector still faces rough times ahead with tough competition, pushback from insurers and slowing volumes. But taking a page from Charles Darwin, analysts at Jefferies ...

  • Alkermes Plc – Value Analysis (NASDAQ:ALKS) : January 5, 2017
    Capital Cube 11 days ago

    Alkermes Plc – Value Analysis (NASDAQ:ALKS) : January 5, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Alkermes Plc a score of 25. Our analysis is based on comparing Alkermes Plc with the following peers – Acorda Therapeutics, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Zogenix, Inc., Novartis AG Sponsored ADR and ... Read more (Read more...)

  • Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : January 4, 2017
    Capital Cube 13 days ago

    Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : January 4, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alkermes Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Capital Cube 26 days ago

    ETFs with exposure to Alkermes Plc : December 21, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Alkermes Plc Here are 5 ETFs with the largest exposure to ALKS-US. Comparing the performance and risk of Alkermes Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock?
    Insider Monkey last month

    Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock?

    We at Insider Monkey have gone over 742 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article, we look at what those funds think of Alkermes Plc (NASDAQ:ALKS) based on that data. […]

  • Zacks Small Cap Research last month

    CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in MDD

    The Clin501-201 study was a randomized, double blind, placebo controlled trial to evaluate the effects of 15 mg of CERC-501 on tobacco withdrawal and reinstatement and to assess craving, mood, and anxiety during 18 hours of abstinence in 66 heavy cigarette smokers (NCT02641028). The company had previously stated that it did not intend to continue development of CERC-501 in nicotine withdrawal regardless of the results, thus the fact that the drug was generally well tolerated is the most important data to come out of the study as the company pivots to developing CERC-501 as a treatment for major depressive disorder (MDD).

  • Zacks Small Cap Research 2 months ago

    CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to CERC-501

    The results showed that the trial failed to show efficacy on the primary endpoint for mean improvement in the Bech-6 scale, which is a subset of the Hamilton Depression Scale (HDRS-17), averaged over Days 2 and 4 post dose. While the result of the trial was disappointing, the company did report a potentially clinically meaningful effect on the Bech-6 and HDRS-17 for the 20 mg dose group on Day 2. The Phase 2 trial was a randomized, double blind, placebo controlled study evaluating the antidepressant effect of 12 mg and 20 mg doses of CERC-301 in MDD patients currently experiencing a severe depressive episode despite stable ongoing treatment with either an SSRI or SNRI (NCT02459236).

  • Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?
    Insider Monkey 2 months ago

    Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?

    Opus Point Partners Management is a New York-based fund led by Michael S. Weiss and Lindsay A. Rosenwald. Opus Point’s equity portfolio is worth $178.32 million as of the end of September, up from $103.54 million at the end of June. The fund invests mainly in healthcare stocks, which amass around 73% of its equity portfolio. […]

  • TheStreet.com 2 months ago

    Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election

    Alkermes (ALKS) CEO Richard Pops said on CNBC that the price of medicine and the type of insurance patients have are both contributing to the drug pricing problem.